Axial Spondyloarthritis (axSpA) Treatment Market is driven by increased disease awareness and diagnosis
The axial spondyloarthritis (axSpA) treatment market consists of therapies for patients suffering from spinal inflammation and associated back pain. axSpA includes both non-radiographic axial spondyloarthritis (nr-axSpA) in which X-rays of the sacroiliac joints appear normal and ankylosing spondylosis (AS) in whichX-rays show definitive damage to the sacroiliac joints.
Common symptoms include chronic inflammatory back pain, fatigue, stiffness and limitations in spinal mobility. Biologics such as tumor necrosis factor (TNF) inhibitors are effective treatments that can significantly reduce signs and symptoms of Axial Spondyloarthritis (axSpA) Treatment Market and inhibit disease progression in many patients.
The axial spondyloarthritis (axSpA) treatment market is estimated to be valued at USD 6.02 billion in 2024 and is expected to reach USD 10 billion by 2031, growing at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2031.
Get more insights on: Axial Spondyloarthritis (axSpA) Treatment Market
Get this Report in Japanese Language: 軸性脊椎関節炎（axSpA）治療市場
Get this Report in Korean Language: 축성 척추관절염(axSpA) 치료 시장
English
Arabic
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian